Circulate Health and Reborne have established a partnership to offer therapeutic plasma exchange in the UK, a procedure that removes and replaces blood plasma using FDA-cleared technology. The procedure is supported by peer-reviewed research from the Buck Institute showing measurable effects on biological age markers in a randomized controlled trial.
Key Points
- TPE removes aged plasma and replaces it with substitute fluid
- Randomized controlled trial showed measurable biological age effects
- First European partnership for Circulate Health's standardized protocol
Longevity Analysis
Therapeutic plasma exchange represents a direct intervention on circulating factors that accumulate with age. The procedure operates on the principle that plasma contains both rejuvenating and age-promoting signals—removing older plasma and introducing substitute fluid addresses a fundamental driver of systemic aging. Clinical validation through randomized controlled trials establishes a foundation for understanding which biomarkers respond and which populations benefit most, critical information for determining whether this intervention justifies the procedural and financial burden in individualized longevity strategies.
Original published by LT Wire.